Vernalis announces positive results for Parkinson's Disease treatment study

AIM-listed pharmaceutical company Vernalis has published positive results for a Receptor Occupancy study of an antagonist with potential applications for Parkinson's disease and other Central Nervous System indications.

AIM-listed pharmaceutical company Vernalis has published positive results for a Receptor Occupancy study of an antagonist with potential applications for Parkinson's disease and other Central Nervous System indications.

The study examined the relationship between dose, plasma concentration and blockade of the so-called "A2A" receptor using positron emission tomography scanning and included a preliminary evaluation, using functional magnetic resonance imaging of the effects of V81444, the particular antangonist, on cognitive function.

The study demonstrated that full A2A blockade could be achieved with single doses that were within the range of doses previously shown to be well tolerated with no safety concerns.

As such, the study has provided confirmation of the appropriate dose to be used in the forthcoming clinical proof-of-concept trial.

Vernalis now plans to initiate, in the first half of next year, a Phase IIa proof-of-concept study to further evaluate the pharmacokinetics, safety and tolerability of V81444 in patients, together with an evaluation of efficacy in a target patient population.

Ian Garland, Chief Executive Officer of Vernalis, commented: "We are very pleased with these results and are already actively preparing for the continued development of this exciting programme over the next 12 months".

Vernalis's share price was up 0.55% to 23p at 09:27 on Wednesday morning.

MF

Recommended

Director dealings w/e 5 August: what company insiders are buying and selling
Stocks and shares

Director dealings w/e 5 August: what company insiders are buying and selling

Directors’ share dealings can often give investors an insight into the sentiment of company insiders. Here are some of the biggest deals by company di…
9 Aug 2022
Britain’s most-bought shares w/e 5 August
Stocks and shares

Britain’s most-bought shares w/e 5 August

A look at Britain’s most-bought shares in the week ending 5 August, providing an insight into how investors are thinking and where opportunities may l…
9 Aug 2022
Where to find inflation-resistant stocks
Investment strategy

Where to find inflation-resistant stocks

Terry Smith’s latest update contains some valuable pointers for investors looking to protect against inflation.
8 Aug 2022
A low-risk way to beat inflation
Share tips

A low-risk way to beat inflation

Demand for care-home places is strong and the sector should be able to raise prices ahead of costs, says Max King.
8 Aug 2022

Most Popular

Are UK house prices finally heading for a crash?
House prices

Are UK house prices finally heading for a crash?

The latest house price figures show a fall of 0.1% in July. With interest rates rising, inflation hitting double figures and a recession on the cards,…
5 Aug 2022
Brace yourself for the return of rationing
Economy

Brace yourself for the return of rationing

Russia is turning off the cheap energy. That is already leading to belt-tightening, says Matthew Lynn. Who will suffer most, and which sectors will th…
5 Aug 2022
Fear of missing out – what should investors do now?
Investment strategy

Fear of missing out – what should investors do now?

Markets have rallied from their mid-June lows. But if you missed out, as most investors did, what should you do now? Max King explains.
8 Aug 2022